バイオバンキング市場レポート：動向、予測、競合分析 (2031年まで)

世界のバイオバンキング市場の将来は、製薬・バイオテクノロジー企業やCRO、学術・研究機関、病院市場に機会があり、有望視されています。世界のバイオバンキング市場は、2025年から2031年までのCAGRが10.5%で、2031年までに推定68億米ドルに達すると予想されています。この市場の主な促進要因は、遺伝子検査と精密医療に対する需要の高まり、新生児の臍帯血幹細胞保存の人気の高まり、仮想バイオバンキングソフトウェアの出現です。

• Lucintelの予測では、製品・サービ別では、装置が予測期間中に最も高い成長を遂げる見込みです。
• 用途別では、再生医療が予測期間中最大のセグメントであり続けると思われます。
• 地域別では、アジア太平洋が予測期間中に最も高い成長が見込まれます。

バイオバンキング市場の戦略的成長機会

バイオバンキング市場には、利用可能なさまざまなアプリケーションの観点から、いくつかの成長機会が存在します。これらの機会を活用することで、利害関係者は研究や公衆衛生への関与を拡大し、最終的には影響を及ぼすことができます。本概要では、バイオバンキングの枠組みにおける成長力学に焦点を当て、主要な成長パターンと、市場の領域拡大によって定義される広範なアプリケーションの展望について説明します。

• ゲノミクス研究：遺伝子バンク構想の動向は、バイオバンキング市場におけるこのような施設への需要を高めています。バイオバンクは、ゲノム研究のために様々な集団や大量のサンプルを提供します。このアプリケーションは、遺伝子多型、疾病開発、疾病管理における治療などの分野での調査を促進します。バイオバンクのケアは、精密で的を絞った医療の他の分野での成長を助けるゲノミクス研究の一部になると考えられています。
• 個別化医療：個別化医療はバイオバンクの機会にとって悩みの種であり、この分野の成長は見逃せないです。バイオバンクは現在、個別化治療や創薬を支援するために、実際の生物学的検体や詳細な臨床歴を用いた調査を促進する立場にあります。この応用により、より信頼性の高い診断と、患者の疾病をより的確に捉えた治療が可能になり、個別化医療分野の開発がさらに促進されます。
• 公衆衛生調査：バイオバンクは、疾病の発生、疾病の発生に影響を及ぼす要因、および疾病の制御や予防を測定する研究を含むがこれらに限定されない疫学的研究だけでなく、健康に基づく研究に不可欠なサンプルの供給源です。成長機会には、疫学的・公衆衛生的アプローチに不可欠なバイオバンク資源の強化が含まれます。これにより、公衆衛生上の問題を解決し、効果的な保健戦略やプログラムを立案・実施する能力が強化されます。
• 医薬品開発と臨床試験：バイオバンクは、あらゆるニーズに対応できる生物学的調査材料を提供するため、医薬品開発や臨床研究の中核をなします。このような機会に参加することは、医薬品開発や臨床研究のニーズに対して製薬会社や研究会社と協力することを意味します。このアプリケーションは、医薬品開発のプロセスを改善しながら、潜在的な医薬品の創出を早める。
• 疾患特異的バイオバンク：疾患特異的バイオバンクの開発は、がん、心血管疾患、希少遺伝性疾患などの構成的バイオバンクが設立される可能性があることから、もう一つの成長分野です。このようなバイオバンクは、疾患、そのバイオマーカー、治療法についての理解を深める上で有益です。このアプリケーションは特定の研究作業を促進するが、特定の疾患の診断と治療のニーズをさらに前進させる。

戦略的バイオバンキングは、バイオバンキング市場に出現した機会を見誤る。ゲノミクス研究、個別化医療、公衆衛生研究、医薬品開発、疾患特異的バイオバンクは、機会や影響が拡大する分野を示しています。これらの機会を活用することで、研究が進展し、個人の医療が改善され、公衆衛生上の重大な問題が解決されます。

バイオバンキング市場の促進要因・課題

バイオバンキング市場は、技術、規制、経済を含むがこれらに限定されない様々な市場促進要因・課題によって特徴付けられています。利害関係者は、市場促進要因・課題を理解することで、市場に参入し、増加の一途をたどる機会を活用する必要があります。

バイオバンキング市場を牽引する要因は以下の通りです：

• 個別化医療に対する需要の増加：近年、個別化医療が重視されるようになり、バイオバンキング市場は大きく成長しています。「個別化治療」という用語は、そのような治療を提供するために必要な大量の生物学的および臨床データを必要とする治療の概念を明確に構造化したものです。バイオバンクは、個別化医療を研究し、医療サービスを向上させるために、広範で包括的かつ精巧なサンプルコレクションを提供することで、この要件を支援しています。
• 研究イニシアチブの新領域への取り込み：ゲノミクス、疫学、研究開発など、研究イニシアチブの範囲が広がっているため、バイオバンクリソースに対する需要が増加しています。このような研究イニシアチブの成長を理解すると、より多くの生物学的標本が必要とされ、その標本は特異的であると同時に、容易に入手でき、アクセスしやすくなっています。バイオバンクは、有意義な科学的貢献をするために、保有する生物試料の数を増やし、様々な研究目的に対応する範囲を広げるプロセスに着手しています。
• 政府および機関からの資金提供：バイオバンキングの構築やそれに関連する研究のために政府や機関から提供される資金は、しばしば市場の中核的な成長要因となっています。資金提供は、新たなバイオバンクの設立や既存のバイオバンクの拡張、研究成果の改善や共有に役立ちます。バイオバンキングの取り組みへの投資の増加は、絶え間ない研究のこの時期に高度なリソースを生み出すのに役立っています。
• 国際協力とデータ共有：国際的なコラボレーションとデータ共有がバイオバンキング市場の成長を刺激しており、この理由により、より大規模で異種なデータセットを扱うことが容易になっています。国際的なパートナーシップやネットワークを通じて、調査や知識交換の機能が開放されます。このような動向により、これまで時間がかかっていた研究が、人材とバイオバンクのリソースを利用することで可能となり、より優れた、より迅速な科学が育まれます。

バイオバンキング市場における課題は以下の通りです：

• 規制と倫理問題：規制と倫理の遵守は、バイオバンキングにとって市場原理以上のものです。データとその保護、関係者の同意、サンプルの取り扱いに関するポリシーに対処することは、非常に時間のかかる事業であり、かなりのコストがかかります。バイオバンクの構造及び運営の枠組みの信頼性と完全性を維持するためには、倫理的配慮と規制の側面を満たす必要があると認識されています。
• データの安全性、保護、プライバシー：データ・セキュリティとプライバシー関連の問題は、バイオバンキング市場の課題の一つです。極めて個人的な健康・生物学的データを漏洩や不正アクセスから保護することは問題です。バイオマスデータを危害から守り、バイオバンクとその業務に対する社会的信頼を確保するために、サイバーセキュリティの実践と法的措置を講じるべきです。
• コストとインフラ資源管理：バイオバンクの設立と運営には多額の財政投資が必要であり、特に小規模な機関にとっては困難が伴います。必要とされる主要な活動のひとつは、運営コストを管理しながら、機器、情報技術システム、および人的資源のための資金を調達することです。コストの抑制と適切な資源管理の実践は、バイオバンクの持続可能性を達成する上で極めて重要な要素となります。

これら3つの結論が達成されるべき具体的な理由を説明するために、さらなる研究が行われ、バイオバンキングの理論的基盤は、応用科学社会学の多くと同様に発展してきました。さらに、技術革命、医療産業におけるパーソナライゼーションの傾向、研究活動の成長を含むがこれらに限定されない主要な動向が、バイオバンキング市場を形成しています。これらの促進要因と市場問題に取り組むことは、成長機会を活用し、研究の可能性を高め、変化するバイオバンキングの現実を克服するために不可欠です。

目次

第1章 エグゼクティブサマリー

第2章 世界のバイオバンキング市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 市場動向と予測分析 (2019年～2031年)

• マクロ経済動向 (2019～2024年) と予測 (2025～2031年)
• 世界のバイオバンキング市場の動向 (2019～2024年) と予測 (2025～2031年)
• 世界のバイオバンキング市場：試料の種類別
  • 血液製品
  • ヒト組織
  • 細胞株
  • 核酸
  • 体液
  • ヒト排泄物
• 世界のバイオバンキング市場：製品・サービス別
  • 装置
  • 消耗品
  • サービス
  • ソフトウェア
• 世界のバイオバンキング市場：用途別
  • 再生医療
  • ライフサイエンス調査
  • 臨床研究
• 世界のバイオバンキング市場：最終用途別
  • 製薬・バイオテクノロジー企業、CRO（医薬品開発業務受託機関）
  • 学術研究機関
  • 病院

第4章 地域別の市場動向と予測分析 (2019年～2031年)

• 世界のバイオバンキング市場：地域別
• 北米のバイオバンキング市場
• 欧州のバイオバンキング市場
• アジア太平洋のバイオバンキング市場
• その他地域のバイオバンキング市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 世界のバイオバンキング市場の成長機会：試料の種類別
  • 世界のバイオバンキング市場の成長機会：製品・サービス別
  • 世界のバイオバンキング市場の成長機会：用途別
  • 世界のバイオバンキング市場の成長機会：最終用途別
  • 世界のバイオバンキング市場の成長機会：地域別
• 世界のバイオバンキング市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界のバイオバンキング市場の生産能力拡大
  • 世界のバイオバンキング市場における企業合併・買収 (M&A)、合弁事業
  • 認証とライセンシング

第7章 主要企業のプロファイル

• Thermo Fisher Scientific
• PHC Holdings
• Becton
• Dickinson and Company
• QIAGEN N.V.
• Merck KGaA
• Avantor
• Cryoport
• Tecan Trading
• Azenta

The future of the global biobanking market looks promising with opportunities in the pharmaceutical & biotechnology company and CRO, academic & research institute, and hospital markets. The global biobanking market is expected to reach an estimated $6.8 billion by 2031 with a CAGR of 10.5% from 2025 to 2031. The major drivers for this market are the growing demand for genetic testing and precision medicine, the rising popularity of preserving newborns' cord blood stem cells, and the emergence of virtual biobanking software.

• Lucintel forecasts that, within the product & service category, equipment is expected to witness the highest growth over the forecast period.
• Within the application category regenerative medicine will remain the largest segment in the forecast period.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Biobanking Market

The biobanking market is changing currently due to the occurrence of new technologies, the rise of new research, and changing policies. New trends signal the movement of biobanks in terms of operations, use of information, and the role played in biomedical research. Such trends are important to those interested in taking advantage of the new, fast-developing, biobanking environment.

• Advanced Technologies Adoption: In order to improve data analysis and sample processing, biobanks are integrating sophisticated tools such as high-throughput sequencing, NGS, and artificial intelligence among others. These technologies maximize the effectiveness of biobank tasks making it possible to conduct in-depth research to reveal genetic and environmental risk factors of health and diseases including illness and stress.
• Growth of Personalized Medicine: One of the trends of the market is also the old reason for the increasing loud demand for bank data that focuses on the cure of a certain disease. New populations and new clinical collections are also expanding and biobanks are making possible research into developing individualized therapies and precision medicine. This trend helps to develop more accurate treatment options and improve the efficacy of medical treatment.
• Safeguarding of Data and its Confidentiality: As focus increases with regard to data privacy and security, biobanks have implemented deep-rooted systems for the protection of such data. Adhering to regulatory frameworks like GDPR and HIPAA has become a vision, and biobanks have stepped up into new horizons of data security including the safeguarding of health and biological data and embracing confidentiality.
• Building of Centrally Managed and Region-Wise Located Biobanks: This current trend has been noticed in numerous countries where they are establishing a common biobank or biobanks with regional offices to enhance population-based studies and other health-related research on a large pop
• Combination of Biobanks and Sharing of Data: More emphasis is made on the increase of the combination, and sharing of data, of the biobanks and research institutions. There are emerging partnerships and networks that make it possible for scientists to utilize many datasets, from which a wide array of research can be pursued, speeding up the pace of discovery. This trend increases the worth of biobank resources and allows for more extensive and effective research.

Building of Centrally Managed and Region-Wise Located Biobanks: This current trend has been noticed in numerous countries where they are establishing a common biobank or biobanks with regional offices to enhance population-based studies and other health-related research on a large pop

Recent Developments in the Biobanking Market

Recent transitions in the biobanking market are characterized by improvements in technological infrastructural and research parameters. These developmental milestones are likely to revolutionize biobanking as they will offer new perspectives on biological sample collection, handling, and analysis for research. Knowledge of these developments is important for the players in the market to understand where the market is headed and identify new possibilities.

• Establishment of Large-Scale Biobanks: The establishment of large-scale biobanks like the All of Us Research Program in the U.S. and the European and Asian national biobanks is worth noting. These biobanks focus on harvesting a wide and rich array of biological samples to conduct extensive research population projects and customized treatment. They deepen the level of detail that can be addressed and assist cutting-edge research in genetics and population health.
• Combining the Various Areas of Genomics with High Throughput Technologies: The combining of genomics and biobanks with high-throughput practices is contributing to the development of research effort expansion. The standard operating procedures include high-throughput sequencing and genomic analysis which now allows the in-depth evaluation of genetic materials and how they affect health and disease. This advancement leads to the generation of more targeted and effective research, which in turn allows for deeper insights and the eradication of even more diseases.
• Biobank Information Management System's Improvements: The recent trends in biobank data management systems are enhancing the effectiveness and speed with which biobanks are operating. Improved techniques of handling the biorepository data as well as bioinformatics software help in proper structuring, dissecting, and disseminating the Biobank data. These systems facilitate the incorporation of different types of data sets and streamline the workflows, hence improving the research output.
• More Attention is Given to Bioethics and Regulations: More attention is paid to the ethical and regulatory perspectives of biobanking. There are measures being put in place by biobanks to make sure that ethics and governance principles such as consent, confidentiality, and sample handling are being followed. This concern improves the efficiency and reliability of the operations of biobanks and promotes compliance with accepted standards.
• Increasing the Scale of Biobank Networks and Advances in Collaborations: The growing network and collaboration of the biobanks is an interesting trend as the biobanks are ready to collaborate for sharing resources and data. These collaborations allow making use of the greater and more varied datasets, benefiting from the synergies of research, and speeding the process of science. Embedding biobanks into global networks helps achieve more complete and significant research results.

Important recent advances in the biobanking field such as the creation of population biobanks, adoption of new information technologies, progress in information management, fulfillment of regulative requirements, and enlargements of networks are defining the evolution of the markets. These changes broaden the possibilities of conducting biobanking research, facilitate personalized medicine, and bring about progress in the healthcare industry as well as in biomedical research.

Strategic Growth Opportunities for Biobanking Market

In the biobanking market, there are several opportunities for growth in terms of the different applications available. By applying these opportunities, stakeholders will be able to enlarge their engagement in and ultimately influence, research and public health. This overview focuses on the biobanking framework growth dynamics and explains the key growth patterns along with prospects for wider applications defined by the domain extension of the market.

• Genomics Research: The trends of Geno-bank initiatives are increasing the demand for such a facility in the biobanking market. The biobanks provide a variety of populations and a large sample for genomic research. This application promotes research in the fields of genetic polymorphism, disease development, and treatments in disease management. Transferring the care of biobanks is looking to portions of the genomics research that will help grow those in other areas of precise and targeted medicine.
• Personalized Medicine: Personalized medicine is a bane for biobank opportunities and the growth of this segment cannot be overlooked. Biobanks are now positioned to facilitate research with actual biological specimens and detailed clinical history in support of individualized therapies and drug discovery. This application allows a more reliable diagnosis and a treatment that better targets the disease of the patient and further promotes the development of the personalized medicine field.
• Public Health Research: Biobanks are sources of samples essential for health-based research as well as for epidemiological studies including but not limited to the studies measuring disease occurrence, factors influencing the occurrence of diseases, and their control or prevention. Growth opportunities include enhancing crucial biobank resources for epidemiological and public health approaches. This enhances the ability to solve public health problems as well as design and implement effective health strategies and programs.
• Drug Development and Clinical Trials: Biobanks are the heart of any drug development or any clinical studies, as they offer biological investigation material for all possible needs. Joining such opportunities means cooperation with pharmaceutical and research companies for the needs of drug development and clinical studies. This application hastens the generation of potential drugs while improving the processes of drug development.
• Disease-Specific Biobanks: Developing disease-specific biobanks is another area for growth as constitutive biobanks such as the ones for cancer, cardiovascular diseases, or rare genetic diseases may be set up. These biobanks are beneficial for the investigation of a better understanding of the disease, its biomarkers, and its treatment options. This application promotes specific research work, however, further advances the needs of diagnosis and treatment of specific diseases.

Strategic biobanking miscues opportunities emerging in the biobanking market. Genomics research, personalization medicine, public health research, drug development, and disease-specific biobanks indicate areas of growing opportunity and impact. Taking advantage of these opportunities engages progress in research, improves individual healthcare, and solves significant public health problems.

Biobanking Market Driver and Challenges

The biobanking market is characterized by various drivers and challenges, including, but not limited to, technology, regulation, and economy. Stakeholders need to appreciate such drivers and challenges in order to maneuver into the market and harness such opportunities that are ever on the rise.

The factors responsible for driving the biobanking market include:

• Increasing Demand Text for Personalized Medicine: Resent emphasis on personalized medicine is a major booster in the biobanking market. The term "personalized treatment" clearly structures the concept of therapy requiring a great amount of biological and clinical data needed to provide such treatment. Biobanks assist this requirement with their provision of broad, comprehensive, and elaborate sample collections to investigate personalized medicine and enhance healthcare services.
• Inclusion of New Areas in Research Initiatives: The demand for biobank resources is increasing because the scope of research initiatives including genomics, epidemiology, and drug development is broadening. Understanding the growth of these research efforts, there is therefore an increasing demand for more biological specimens that are specific as well as easily available and accessible. Biobanks have embarked on the process of increasing the number of biological specimens that they have and the scope at which they serve different research purposes to make meaningful scientific contributions.
• Government and Institutional Funding: Often, funding provided by the government and the institutions for building and biobanking and research related to it constitutes the core growing factor of the market. Funding helps to set up new biobanks and extend existing ones, to improve research work and to help share it. Increased investment in biobanking initiatives helps to create advanced resources during this period of constant research.
• International Collaboration and Data Sharing: International collaboration and data sharing are stimulating the growth of the biobanking market and due to this reason, it is easier to work with larger and more heterogeneous sets of data. Research and knowledge exchange capabilities are opened up through international partnerships and networks. This trend fosters better and faster science as research that would have taken longer to conduct is made possible by the availability of talent and biobank resources.

Challenges in the biobanking market are:

• Regulation and Ethical Issues: Regulatory and ethical compliance is more than one of the market forces for biobanking. Dealing with policies regarding the data and its protection, consent of parties and sample handling can be a very slow undertaking quite expensive. It is recognized that ethical considerations and regulatory aspects should be met to retain the credibility and integrity of the biobank structure and operational framework.
• Data Security, Protection, and Privacy: Data security and privacy-related issues are among the biobanking market challenges. Safeguarding very personal health-biological data from leakage and abusive access is an issue. Cybersecurity practices and legal measures should be performed to protect biomass data from harm and ensure public confidence in biobanks and their practices
• Costs and Infrastructure Resource management: Setting up and running biobanks will involve significant financial investments which particularly for small institutions can prove a challenge. One of the major activities that will be required is sourcing funds for equipment, information technology systems as well as human resources while controlling operational costs. Cost containment and proper resource management practices will be critical factors in the achievement of sustainability of the biobank.

Further studies have been done to illustrate specific reasons why these three conclusions should be achieved, the theoretical base of biobanking has been developed as much of the applied sociology of science. Further, the major forces including but not limited to the technological revolution, the personalization trend in the healthcare industry, and the growth in research activity take the shape of the biobanking market. Tackling these drivers and Market problems is essential for utilizing growth opportunities, increasing the research possibilities, and conquering the changing reality of biobanking.

List of Biobanking Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies biobanking companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the biobanking companies profiled in this report include-

• Thermo Fisher Scientific
• PHC Holdings
• Becton
• Dickinson and Company
• QIAGEN N.V.
• Merck KGaA
• Avantor
• Cryoport
• Tecan Trading
• Azenta

Biobanking by Segment

The study includes a forecast for the global biobanking market by sample type, product & service, application, end use, and region.

Biobanking Market by Sample Type [Analysis by Value from 2019 to 2031]:

• Blood Products
• Human Tissues
• Cell Lines
• Nucleic Acids
• Biological Fluids
• Human Waste Products

Biobanking Market by Product & Service [Analysis by Value from 2019 to 2031]:

• Equipment
• Consumables
• Services
• Software

Biobanking Market by Application [Analysis by Value from 2019 to 2031]:

• Regenerative Medicine
• Life Science Research
• Clinical Research

Biobanking Market by End Use [Analysis by Value from 2019 to 2031]:

• Pharmaceutical & Biotechnology Companies and CROs
• Academic & Research Institutes
• Hospitals

Biobanking Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Biobanking Market

The biobanking market has evolved positively due to technological advancements, increased research demands, and a focus on personalized medicine. Biobanks play a crucial role in medical research and therapy development by collecting and preserving biological specimens. Insights into the biobanking landscape in the USA, China, Germany, India, and Japan illustrate the scale and direction of the market amid changing policies and technologies.

• United States: In the U.S., biobanking has made significant strides through the integration of high-throughput gene sequencing and bioinformatics. Initiatives like the All of Us Research Program focus on broad data collection to improve services. Increased funding and public-private partnerships are enhancing biobank capabilities and supporting advances in disease therapeutics and research.
• China: China has heavily invested in its biobanking network, driven by government policies aimed at enhancing biotechnological capabilities and healthcare systems. This includes creating large-scale biobanks and forming collaborations with global organizations. China is also working to advance its legislative policies to ensure the ethical use and security of biological materials and data.
• Germany: Germany's biobank growth is supported by robust legislation and high standards for handling patient data and bioethics. The German Biobank Node promotes European data collection and sharing for scientific purposes. Recent efforts focus on integrating biobank data with clinical information to enhance research and precision medicine initiatives.
• India: India's biobanking segment is developing due to increasing research activities and government support for biomedical initiatives. New biobanks and expansions of existing ones, such as the Indian Genome Variation Consortium, are emerging. The country aims to strengthen infrastructure and data support for genomics, personalized medicine, and public health research through international partnerships.
• Japan: Japan's biobanking market is evolving through technological advancements and personalized medicine strategies. Recent developments include large-scale biobanks and partnerships with international counterparts. Japan is also working to integrate biobank data with electronic health records to improve research and clinical care while enhancing regulatory and ethical frameworks.

Features of the Global Biobanking Market

Market Size Estimates: Biobanking market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Biobanking market size by various segments, such as by product & service, sample type , application, end use industry, and region in terms of ($B).

Regional Analysis: Biobanking market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product & service, sample types , applications, end use industries, and regions for the biobanking market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the biobanking market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the biobanking market by sample type (blood products, human tissues, cell lines, nucleic acids, biological fluids, and human waste products), product & service (equipment, consumables, services, and software), application (regenerative medicine, life science research, and clinical research), end use (pharmaceutical & biotechnology companies and CROs, academic & research institutes, and hospitals), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Biobanking Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Biobanking Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Biobanking Market by Sample Type
  • 3.3.1: Blood Products
  • 3.3.2: Human Tissues
  • 3.3.3: Cell Lines
  • 3.3.4: Nucleic Acids
  • 3.3.5: Biological Fluids
  • 3.3.6: Human Waste Products
• 3.4: Global Biobanking Market by Product & Service
  • 3.4.1: Equipment
  • 3.4.2: Consumables
  • 3.4.3: Services
  • 3.4.4: Software
• 3.5: Global Biobanking Market by Application
  • 3.5.1: Regenerative Medicine
  • 3.5.2: Life Science Research
  • 3.5.3: Clinical Research
• 3.6: Global Biobanking Market by End Use
  • 3.6.1: Pharmaceutical & Biotechnology Companies and CROs
  • 3.6.2: Academic & Research Institutes
  • 3.6.3: Hospitals

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Biobanking Market by Region
• 4.2: North American Biobanking Market
  • 4.2.1: North American Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.2.2: North American Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals
• 4.3: European Biobanking Market
  • 4.3.1: European Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.3.2: European Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals
• 4.4: APAC Biobanking Market
  • 4.4.1: APAC Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.4.2: APAC Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals
• 4.5: ROW Biobanking Market
  • 4.5.1: ROW Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.5.2: ROW Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Biobanking Market by Sample Type
  • 6.1.2: Growth Opportunities for the Global Biobanking Market by Product & Service
  • 6.1.3: Growth Opportunities for the Global Biobanking Market by Application
  • 6.1.4: Growth Opportunities for the Global Biobanking Market by End Use
  • 6.1.5: Growth Opportunities for the Global Biobanking Market by Region
• 6.2: Emerging Trends in the Global Biobanking Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Biobanking Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biobanking Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Thermo Fisher Scientific
• 7.2: PHC Holdings
• 7.3: Becton
• 7.4: Dickinson and Company
• 7.5: QIAGEN N.V.
• 7.6: Merck KGaA
• 7.7: Avantor
• 7.8: Cryoport
• 7.9: Tecan Trading
• 7.10: Azenta